Clinical Trial: Acceptability and Adherence to Different Dosing Regimens of the Multistrain Probiotic Vivomixx(R) 460 Neo 9 in Adults Receiving Antibiotic Therapy.

U.S., Feb. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07380009) titled 'Acceptability and Adherence to Different Dosing Regimens of the Multistrain Probiotic Vivomixx(R) 460 Neo 9 in Adults Receiving Antibiotic Therapy.' on Dec. 21, 2025.

Brief Summary: This open-label interventional study aims to evaluate the acceptability and adherence of adult participants to the multistrain probiotic Vivomixx(R) 460 Neo 9 when administered concurrently with antibiotic therapy. Participants are randomized to receive one of two dosing regimens: a low daily dose or a high daily dose. The study will assess the effects of these regimens on the prevention of antibiotic-associated diarrhea (AAD), gastrointestinal symptoms, ...